Patents Assigned to IMMUNEXPRESS PTY LTD
-
Patent number: 11884978Abstract: Disclosed are compositions, methods and apparatus for diagnosing and/or monitoring a virus-associated systemic inflammation by measurement of a host immune response. The invention can be used for diagnosis including early diagnosis, monitoring, making treatment decisions, or management of subjects suspected of having systemic inflammation associated with an infection. More particularly, the present disclosure relates to peripheral blood RNA and protein biomarkers that are useful for specifically distinguishing between the host systemic immune response to viruses as compared to the host immune response to other causes of systemic inflammation.Type: GrantFiled: September 30, 2016Date of Patent: January 30, 2024Assignee: IMMUNEXPRESS PTY LTDInventors: Richard Bruce Brandon, Brian Andrew Fox, Leo Charles McHugh, Dayle Lorand Sampson
-
Patent number: 11047010Abstract: The present invention discloses methods, kits, and apparatus as well as reagents and compositions associated therewith for deriving an indicator for use in diagnosing the presence, absence or degree of at least one condition in a biological subject or in prognosing at least one condition in a biological subject. Also disclosed is a biomarker signature for use in diagnosing the presence, absence or degree of at least one condition in a biological subject or in prognosing at least one condition in a biological subject. The present invention further discloses methods, kits and apparatus, as well as reagents and compositions associated therewith, for identifying biomarkers for use in a biomarker signature.Type: GrantFiled: February 6, 2015Date of Patent: June 29, 2021Assignee: ImmuneXpress Pty LtdInventors: Richard Bruce Brandon, Leo Charles McHugh
-
Patent number: 10975437Abstract: Disclosed are methods for treating or inhibiting the development of infection-negative systemic inflammatory response syndrome (inSIRS) or infection-positive systemic inflammatory response syndrome (ipSIRS) based on the use of complement component 3a receptor 1 (C3AR1) as a biomarker for differentiating between inSIRS and ipSIRS.Type: GrantFiled: November 8, 2018Date of Patent: April 13, 2021Assignee: ImmuneXpress Pty LtdInventors: Richard Bruce Brandon, Leo Charles McHugh
-
Patent number: 10865447Abstract: The present invention discloses methods, kits, and apparatus as well as reagents and compositions associated therewith for deriving an indicator for use in diagnosing the presence, absence or degree of at least one condition in a biological subject or in prognosing at least one condition in a biological subject. Also disclosed is a biomarker signature for use in diagnosing the presence, absence or degree of at least one condition in a biological subject or in prognosing at least one condition in a biological subject. The present invention further discloses methods, kits and apparatus, as well as reagents and compositions associated therewith, for identifying biomarkers for use in a biomarker signature.Type: GrantFiled: May 15, 2015Date of Patent: December 15, 2020Assignee: ImmuneXpress Pty LtdInventors: Richard Bruce Brandon, Leo Charles McHugh
-
Patent number: 10719579Abstract: A method for validating quantification of biomarkers, the biomarkers being quantified using a quantification technique of a selected type, and the method including determining a plurality of biomarker values, each biomarker value being indicative of a value measured or derived from a measured value, for at least one corresponding biomarker of the biological subject and being at least partially indicative of a concentration of the biomarker in a sample taken from the subject, determining at least one control value by determining a combination of biomarker values, comparing each control value to a respective control reference and determining if the biomarker values are valid using results of the comparison.Type: GrantFiled: May 20, 2016Date of Patent: July 21, 2020Assignee: IMMUNEXPRESS PTY LTDInventor: Leo Charles McHugh
-
Patent number: 10364474Abstract: Disclosed are methods for identifying and/or classifying microbes using one or more single nucleotide polymorphisms (SNPs) in 16S ribosomal RNA (16S rRNA) of prokaryotes and/or one or more SNPs in 5.8S ribosomal RNA (5.8S rRNA) of eukaryotes. Also disclosed are probes, primers and kits that are useful in those methods. Methods for the diagnosis of sepsis based upon these SNPs are also disclosed.Type: GrantFiled: May 29, 2014Date of Patent: July 30, 2019Assignee: IMMUNEXPRESS PTY LTDInventors: Richard Bruce Brandon, Flavia Huygens
-
Patent number: 10190169Abstract: Disclosed are method and apparatus for identifying biomarkers and in particular for identifying biomarkers for use in making clinical assessments, such as early diagnostic, diagnostic, disease stage, disease severity, disease subtype, response to therapy or prognostic assessments. In one particular example, the techniques are applied to allow assessments of patients suffering from, suspected of suffering from, or with clinical signs of SIRS (Systemic Inflammatory Response Syndrome) being either infection-negative SIRS or infection-positive SIRS.Type: GrantFiled: June 18, 2014Date of Patent: January 29, 2019Assignee: ImmuneXpress Pty LtdInventors: Richard Bruce Brandon, Leo Charles McHugh
-
Patent number: 10167511Abstract: Disclosed are method and apparatus for identifying biomarkers and in particular for identifying biomarkers for use in making clinical assessments, such as early diagnostic, diagnostic, disease stage, disease severity, disease subtype, response to therapy or prognostic assessments. In one particular example, the techniques are applied to allow assessments of patients suffering from, suspected of suffering from, or with clinical signs of SIRS (Systemic Inflammatory Response Syndrome) being either infection-negative SIRS or infection-positive SIRS.Type: GrantFiled: July 2, 2016Date of Patent: January 1, 2019Assignee: IMMUNEXPRESS PTY LTDInventors: Richard Bruce Brandon, Leo Charles McHugh
-
Patent number: 9816128Abstract: The invention discloses isolated endotoxemia marker polynucleotides selected from any one of 163 different polynucleotide sequences, or variants thereof. Endotoxemia related conditions are diagnosed in a test subject by aberrant expression of at least one of the endotoxemia markers or variants thereof. Of practical use, is the early diagnosis of disease, determining those animals at risk of developing endotoxemia, monitoring of an animals immune response to the disease and the enablement of better treatments. Of particular interest is the diagnosis of laminitis in hoofed animals, including horses.Type: GrantFiled: January 30, 2013Date of Patent: November 14, 2017Assignee: IMMUNEXPRESS PTY LTDInventors: Richard Bruce Brandon, Mervyn Rees Thomas
-
Publication number: 20160237493Abstract: Disclosed are method and apparatus for identifying biomarkers and in particular for identifying biomarkers for use in making clinical assessments, such as early diagnostic, diagnostic, disease stage, disease severity, disease subtype, response to therapy or prognostic assessments. In one particular example, the techniques are applied to allow assessments of patients suffering from, suspected of suffering from, or with clinical signs of SIRS (Systemic Inflammatory Response Syndrome) being either infection-negative SIRS or infection-positive SIRS.Type: ApplicationFiled: June 18, 2014Publication date: August 18, 2016Applicant: ImmuneXpress Pty LtdInventors: Richard Bruce BRANDON, Leo Charles MCHUGH
-
Publication number: 20140037649Abstract: Disclosed are methods and apparatus for diagnosis, detection of host response, monitoring, treatment or management of sepsis, infection-negative systemic inflammatory response syndrome (SIRS) and post-surgical inflammation in mammals. More particularly, the present invention discloses marker genes and their splice variant transcripts as well as their expression products, which are useful for distinguishing between sepsis and infection-negative SIRS, including post-surgical inflammation, and to the use of these markers in grading, monitoring, treatment and management of these conditions.Type: ApplicationFiled: November 24, 2011Publication date: February 6, 2014Applicant: IMMUNEXPRESS PTY LTDInventors: Richard Bruce Brandon, Mervyn Rees Thomas, Glenn Stone